Research
-
LyondellBasell (LYB): Margin Normalization Story, Not Growth — Equity Research
LyondellBasell Industries N.V. (LYB) earns a HOLD rating as valuation reflects a cyclical chemicals rebound more than durable growth. Q1 2026 EBITDA improved to $617M, but oversupply and weak margins keep the investment case tied to normalization.
-
Intuitive Surgical (ISRG): Premium Robotics Multiple, Hold Stance
Intuitive Surgical (ISRG) earns a HOLD rating as its dominant robotic surgery franchise and $2.25B of TTM levered free cash flow are offset by a rich valuation. China tender disruption remains the key near-term overhang.
-
UTF: Cheap on P/E, but Cash Conversion Still Clouds the Case | Equity Research
UTF is rated HOLD as its low 6.8x trailing P/E is offset by weak cash generation and limited liquidity. Despite strong operating margins and solid ROE, operating cash flow remains negative, making the current setup hard to underwrite.
-
Celsius Holdings (CELH): Pepsi Moat vs Concentration Risk | Analysis
Celsius Holdings (CELH) is rated as a growth-first functional beverage story with a hard-to-replicate Pepsi distribution moat. But 43.2% of 2025 revenue tied to Pepsi makes concentration risk the central investment debate.
-
Willdan Group (WLDN) Energy Efficiency — Equity Research
Willdan Group (WLDN) is a Buy-rated energy efficiency and engineering services name with sticky utility relationships and a nationwide footprint. Despite modest margins, the company’s 18.8x forward P/E and leveraged balance sheet make cash flow execution central to the investment case.
-
General Electric (GE) Industrial Automation — Equity Research
General Electric (GE) is rated Neutral in this equity research report. The stock trades at 7.2x EV/revenue, while revenue growth of 24.9% YoY points to durable demand but also a valuation that assumes margin resilience.
-
UiPath Inc. (PATH) Enterprise Automation — Equity Research
UiPath Inc. (PATH) is rated a cautious buy in this equity research note, with a strong enterprise automation moat and 81% gross margins. However, ARR growth slowed to 11% and retention eased to 107%, tempering the acceleration story.
-
Abbott Laboratories (ABT) Medical Devices — Equity Research
Abbott Laboratories (ABT) earns a Buy rating on durable diagnostics and device moats, strong margins, and resilient cash generation. Exact Sciences adds growth optionality, but the pending deal also raises leverage and refinancing risk.
-
Verizon Communications Inc. (VZ) Wireless Network — Equity Research
Verizon Communications Inc. (VZ) is rated Hold as its scale and network moat remain intact, but leverage is elevated. With $200.9B of debt and a 0.60x current ratio, the investment case hinges on dividend support, fiber growth, and refinancing discipline.
-
Fastly, Inc. (FSLY) Edge Cloud Platform — Equity Research
Fastly, Inc. (FSLY) is rated a constructive hold on its programmable edge cloud platform and durable gross margins. Positive free cash flow and 81% gross margin support the thesis, though debt and customer concentration remain key risks.